Chimeric 7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty

scientific article published on 01 January 1999

Chimeric 7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/S0735-1097(98)00532-4
P698PubMed publication ID9935015

P2093author name stringN S Kleiman
C W Smith
B J Hughes
M N Ali
J K Mickelson
T W Chow
N M Lakkis
P2860cites workA comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study GroupQ28245560
Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigmQ29547181
Chemotactic factors regulate lectin adhesion molecule 1 (LECAM-1)-dependent neutrophil adhesion to cytokine-stimulated endothelial cells in vitroQ34237390
Recruitment of CD11b/CD18 to the neutrophil surface and adherence-dependent cell locomotionQ35608005
P-selectin glycoprotein ligand-1 mediates rolling of human neutrophils on P-selectinQ36382391
Motility and adhesiveness in human neutrophils. Effects of chemotactic factorsQ37035630
In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and functionQ37273254
Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIbbeta3 and stimulated by platelet-activating factorQ37373855
Prevention of restenosis after percutaneous transluminal coronary angioplasty: the search for a "magic bullet".Q37773499
The basis of molecular strategies for treating coronary restenosis after angioplastyQ40749553
Defining coronary restenosis. Newer clinical and angiographic paradigmsQ40836276
7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1.Q41123265
Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularizationQ44612131
PTCA: periprocedural platelet activation. Part II of the Duesseldorf PTCA platelet study (DPPS)Q52521791
Platelet activation and coronary stent implantation. Effect of antithrombotic therapy.Q53366355
Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death.Q55060856
Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six monthsQ56945638
Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent plateletsQ59065667
Modulation of Platelet Surface Adhesion Receptors during Cardiopulmonary BypassQ67702157
Granulocyte activation after coronary angioplasty in humansQ68466449
Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac deathQ70014087
Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusionQ70058588
Platelet function in acute myocardial infarction treated with direct angioplastyQ70866651
Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot StudyQ70908805
Neutrophil and platelet activation at balloon-injured coronary artery plaque in patients undergoing angioplastyQ71038217
Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte contentQ71102869
Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease?Q71518090
Increased neutrophil-platelet adhesion in patients with unstable anginaQ71571191
Long-term (4- to 6-year) outcome of Palmaz-Schatz stenting: paucity of late clinical stent-related problemsQ71606924
Neutrophil activation after percutaneous transluminal coronary angioplastyQ71660707
Expression of polymorphonuclear leukocyte adhesion molecules and its clinical significance in patients treated with percutaneous transluminal coronary angioplastyQ71724509
Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptorsQ71827452
Increased expression of neutrophil and monocyte adhesion molecules in unstable coronary artery diseaseQ72227001
Modulation of the expression of the granulocyte adhesion molecule, CR3, by percutaneous transluminal coronary angioplasty and contrast mediaQ72402603
Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatmentQ72571519
Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphologyQ72708405
Thrombin generation in human coronary arteries after percutaneous transluminal balloon angioplastyQ72726624
Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplastyQ73310480
Induction of cytokine expression in leukocytes by binding of thrombin-stimulated plateletsQ73384671
Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapyQ73951493
Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery diseaseQ74172108
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectangioplastyQ539795
P304page(s)97-106
P577publication date1999-01-01
P1433published inJournal of the American College of CardiologyQ2984355
P1476titleChimeric 7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty
P478volume33

Reverse relations

cites work (P2860)
Q37316783A bumpy and winding but right path to domestic drug-eluting coronary stents
Q28196075Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation
Q28165999Adjunctive Pharmacotherapy before Percutaneous Coronary Intervention in Non-ST-Elevation Acute Coronary Syndromes: The Role of Modulating Inflammation
Q37221177Anti-inflammatory effect of abciximab-coated stent in a porcine coronary restenosis model
Q38521611Effect of abciximab on myocardial salvage in patients with acute myocardial infarction undergoing primary angioplasty.
Q43264728Effect of high bolus dose tirofiban on the inflammatory response following percutaneous coronary intervention
Q42238584Evolving coronary stents coated with new bioactive agents
Q73740288IIb's are not IIb's
Q47437758Inflammation as a therapeutic target: a unique role for abciximab
Q58411837Inhibition by soya isoflavones of human polymorphonuclear leukocyte function: possible relevance for the beneficial effects of soya intake
Q51798983Material‐induced tissue factor expression but not CD11b upregulation depends on the presence of platelets
Q44346890Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization
Q64106613Neutrophils disturb pulmonary microcirculation in sepsis-induced acute lung injury
Q35090367Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction
Q34875121Oxidative stress and neutrophil activation--the two keystones of ischemia/reperfusion injury.
Q33862443Platelets and restenosis
Q36679440Rationale for intracoronary administration of abciximab
Q33933810Reperfusion injury after focal myocardial ischaemia: polymorphonuclear leukocyte activation and its clinical implications
Q56944889The benefit of abciximab in percutaneous coronary revascularization is not device-specific
Q35936923The long-term clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (Abciximab: Reopro) coated stent in patients with coronary artery disease